- Home
- ACLX
ACLX
Arcellx Inc.
as 10-24-2025 3:51pm EST
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 4.4B | IPO Year: | 2022 |
| Target Price: | $113.08 | AVG Volume (30 days): | 548.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.86 - $107.37 | Next Earning Date: | 11-07-2025 |
| Revenue: | $56,979,000 | Revenue Growth: | -60.63% |
| Revenue Growth (this year): | -59.13% | Revenue Growth (next year): | 210.73% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Oct 15 '25 | Sell | $91.04 | 5,364 | $488,315.49 | 8,466 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Oct 6 '25 | Sell | $86.22 | 1,064 | $91,733.29 | 8,466 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Oct 3 '25 | Sell | $86.00 | 4,882 | $419,869.58 | 8,466 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Sep 30 '25 | Sell | $81.40 | 21,034 | $1,709,722.59 | 624 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Sep 29 '25 | Sell | $80.16 | 73 | $5,851.68 | 624 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Barrons.com
22 days ago
Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock.
MT Newswires
24 days ago
Arcellx Insider Sold Shares Worth $1,709,723, According to a Recent SEC Filing
BioPharma Dive
2 months ago
Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius
Clinical Trials Arena
4 months ago
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
MT Newswires
4 months ago
Citigroup Initiates Arcellx at Buy With $110 Price Target
Business Wire
5 months ago
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
Insider Monkey
5 months ago
Baron Discovery Fund Initiated a Position in Arcellx (ACLX)
MT Newswires
5 months ago
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.